From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events

Author:

Sutanto Henry12ORCID,Safira Ardea12,Fetarayani Deasy123ORCID

Affiliation:

1. Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

2. Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

3. Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Abstract

The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for various malignancies by harnessing the body’s immune system to target cancer cells. However, their widespread use has unveiled a spectrum of immune-related adverse events, highlighting a critical balance between antitumor immunity and autoimmunity. This review article delves into the molecular immunology of ICIs, mapping the journey from their therapeutic action to the unintended induction of immune-related adverse events. We provide a comprehensive overview of all available ICIs, including cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1, programmed death-ligand 1 inhibitors, and emerging targets, discussing their mechanisms of action, clinical applications, and the molecular underpinnings of associated immune-related adverse events. Special attention is given to the activation of autoreactive T cells, B cells, cytokine release, and the inflammatory cascade, which together contribute to the development of immune-related adverse events. Through a molecular lens, we explore the clinical manifestations of immune-related adverse events across organ systems, offering insights into diagnosis, management, and strategies to mitigate these adverse effects. The review underscores the importance of understanding the delicate interplay between enhancing antitumor responses and minimizing immune-related adverse events, aiming to guide future research and the development of next-generation ICIs with improved drug safety profiles.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference118 articles.

1. Emerging strategies for cancer immunoprevention.;Roeser;Oncogene,2015

2. Breast cancer immunotherapy: an update.;Makhoul;Breast Cancer (Auckl),2018

3. The dawn of vaccines for cancer prevention.;Finn;Nat Rev Immunol,2017

4. Advances in cancer immunology and cancer immunotherapeutics.;Kumar;IJMIO,2018

5. Delivery of ANTI-PD-1 gene with recombinant adeno-associated virus (RAAV) as preventive and curative therapy of infectious diseases in childhood: literature review.;Afla;Curr Int Med Res Prac Surabaya J,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3